The member of the Political Bureau of the Communist Party of Cuba and General Director of the CIGB, PhD. in Sciences Marta Ayala Ávila, clarified that efficacy should not be confused with effectiveness, since the first parameter is measured in a clinical essay scenario, that presuppose ideal conditions, while the effectiveness is analyzed in real life circumstances.

Last July, the Cuban regulatory authority granted Abdala the Authorization for Emergency Use after showing an efficacy of 92.8% in the prevention of the symptomatic disease, during Phase III of clinical trials.

The Abdala vaccine, developed by the Center for Genetic Engineering and Biotechnology (Centro de Ingeniería Genética y Biotecnología, CIGB), has shown 90% effectiveness in severe Covid 19 patients, even with the circulation of aggressive variants such as Delta of the SARS-COV 2 Coronavirus.

The information was posted on Twitter by this scientific institution that created the drug, which in July received, by the Cuban regulatory authority, the Authorization of Emergency Use, after demonstrating 92.8% efficacy in the prevention of the symptomatic disease, during Phase III clinical trials conducted in the provinces of Gramma, Guantánamo and Santiago de Cuba, with more than 40 000 volunteers.

Between the clinical trials, the intervention study, the health intervention in groups and the mass vaccination, more than 14 million doses of the immunogenic have been administered in the country.

In recent days, scientists from CIGB and the Finlay Vaccine Institute (Instituto Finlay de Vacunas, institute that created vaccine candidates Soberana 02 and Soberana Plus), together with BiocubaFarma authorities, presented the representatives of the World Health Organization, the research data developed to create, test and apply these national drugs against Covid-19, in order to be recognized by the global health entity.

Source: Gramma